

A<sup>8</sup>  
cont. --50. (New) The polypeptide according to claim 14  
wherein the said SGK is SGK1, SGK2 $\alpha$ , SGK2 $\beta$  or SGK3.--

---

**REMARKS**

Claims 1-44 are presented for examination in the subject application, as published. By this preliminary amendment, claims 13, 18-21, 24, 28-30, 34, 37 and 42-44 have been amended to adjust the dependencies of the claims. New claims 45-50 have been added.

Respectfully submitted,

Dated: 14 June 2001

Susan J. Braman  
Susan J. Braman  
Reg. No. 34,103

Braman & Rogalskyj, LLP  
P.O. Box 352  
Canandaigua, New York 14424-0352  
Telephone: (716) 393-3002  
Facsimile: (716) 393-3001

13. (Amended) A fusion polypeptide according to claim 11 [or 12 or] wherein the fusion polypeptide comprises a fragment of human SGK or variant or derivative thereof wherein residues equivalent to the N-terminal about 20, 30, 40, 50 or 60 amino acids of human full-length SGK1 are not present.

18. (Amended) A polynucleotide encoding a polypeptide as defined in [any one of claims 11 to 17] claim 11 or claim 14.

19. (Amended) A recombinant polynucleotide suitable for expressing a polypeptide as defined in [any one of claims 11 to 17] claim 11 or claim 14.

20. (Amended) A host cell comprising a polynucleotide [or] as defined in claim 18 [or 19].

21. (Amended) A method of making the polypeptide as defined in [any one of claims 11 to 17] claim 11 or claim 14 the method comprising culturing a host cell comprising a recombinant polynucleotide or a replicable vector which encodes said polypeptide, and isolating said polypeptide from said host cell.

24. (Amended) A polypeptide obtainable by the method of [any one of claims 21 to 23] claim 21.

28. (Amended) The method of [any one of claims 25 to 27] claim 25 or claim 26 wherein the SGK is SGK activated by phosphorylation.

29. (Amended) The method of [any one of claims 24 to 28] claim 25 or claim 26 wherein the activity of the SGK is decreased in the presence of the compound.

30. (Amended) The method according to claim 25 or claim 26 wherein the activity of the SGK is increased in the presence of the compound.

34. (Amended) A kit of parts useful in carrying out a method according to any one of claims [25 to 33] 25, 26, 31, 32 or 33.

37. (Amended) A compound identifiable or identified by a method according to any one of claims [25 to 33] 25, 26, 31, 32 or 33.

42. (Amended) The use according to claim 39 [or method according to claim 40] wherein the patient has cancer.

43. (Amended) The use according to claim 39 [or method according to claim 40] wherein the patient has diabetes or ischaemic disease.

44. (Amended) The method [, use, fusion polypeptide, polypeptide or kit of parts] according to any one of claims [1 to 17, 25 to 33, 35, 39 to 43] 1, 2, 7, 8, 25, 26 or 31-33 wherein the said SGK is SGK1, SGK2 $\alpha$ , SGK2 $\beta$  or SGK3.

45. (New) A host cell comprising a polynucleotide as defined in claim 19.

46. (New) The method according to claim 40 wherein the patient has cancer.

47. (New) The method according to claim 40 wherein the patient has diabetes or ischaemic disease.

48. (New) The use according to any one of claims 5, 6 or 41 wherein the said SGK is SGK1, SGK2 $\alpha$ , SGK2 $\beta$  or SGK3.

49. (New) The fusion polypeptide according to claim 11 wherein the said SGK is SGK1, SGK2 $\alpha$ , SGK2 $\beta$  or SGK3.

50. (New) The polypeptide according to claim 14 wherein the said SGK is SGK1, SGK2 $\alpha$ , SGK2 $\beta$  or SGK3.